Translational Research in Cancer: Time to Reevaluate
نویسندگان
چکیده
منابع مشابه
Is it time to reevaluate definitive therapy in prostate cancer?
In this issue of the Journal, Hoffman et al. (1) explore one of the many unanswered questions confronting newly diagnosed prostate cancer patients: Which definitive treatment is superior—radical prostatectomy (RP) or external beam radiotherapy (EBRT)? The authors analyzed an observational cohort from the population-based Prostate Cancer Outcomes Study treated in the mid-1990s, and the resulting...
متن کاملTranslational Antidote Research: A Bedside to Bench Tale
Although antidote development should proceed in an orderly fashion from observation, to experimental and safety studies, to clinical trials, this sequence is not always precisely followed. The development of fomepizole as an antidote for toxic alcohol and glycol poisoning is an example of how this may not be the case. Interest in the development of fomepizole was spurred in the 1960s. Shortly t...
متن کاملTranslational research in breast cancer.
Translational research (TR) involves both the development of novel diagnostics and novel therapeutics. These two major developmental areas are often associated with each other and these associations often bring new paradigms in the management of cancer patients. For example, the development of trastuzumab-based treatments has been conducted in harmony with the development of new methodologies t...
متن کاملTranslational research in breast cancer.
routine. This also explains the interest of a larger public in these issues; breast cancer activists are willing to take up a role in the creation of biological and clinical databases. Patients are asked to lobby for and help in clinical studies. On the other hand, the access to human tissues is only possible via the patient. The discussion around the Human Tissue Act in Britain may serve as on...
متن کاملTranslational Research in Pancreatic Cancer
169: KRAS mutations in a population of patients operated for pancreatic adenocarcinoma [5] Researchers from Denmark presented a translational study on KRAS mutations in early pancreatic cancer. Previous reports had showed that the frequency of KRAS gene mutations in pancreatic cancer was as high as 75-90% [2]. This high percentage of KRAS mutations was representative of all pancreatic cancer st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pathobiology
سال: 2009
ISSN: 1423-0291,1015-2008
DOI: 10.1159/000245892